Endologix has announced that the US Centers for Medicare & Medicaid Services (CMS) recently granted a New Technology Add-on Payment (NTAP) for the Detour system, a US Food and Drug Administration (FDA)-designated Breakthrough Device, as part of its Fiscal Year 2024 Hospital Inpatient Prospective Payment System.
An Endologix press release notes that NTAP was created to facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries. Beginning 1 October 2023, CMS will provide hospitals with additional device reimbursement when the Detour system is used for eligible cases in the hospital inpatient setting.
According to Endologix, percutaneous transmural arterial bypass (PTAB) with the Detour system offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to bypass lesions in the superficial femoral artery, by using conduits routed through the femoral vein via a transmural passage, to restore blood flow to the leg. This approach is effective for patients with long lesions (20–46cm in length), those that have already undergone failed endovascular procedures, or those that may be suboptimal candidates for open surgical bypass.
“Receiving the NTAP designation is a testament to the transformative potential of the Detour system in treating complex PAD. At Endologix, we are deeply committed to pioneering solutions that drive better patient outcomes. With this added support from CMS for eligible patients, we are excited to see more patients benefit from this novel approach,” said Matt Thompson, president, and CEO of Endologix.
